IN2014DN10899A - - Google Patents
Info
- Publication number
- IN2014DN10899A IN2014DN10899A IN10899DEN2014A IN2014DN10899A IN 2014DN10899 A IN2014DN10899 A IN 2014DN10899A IN 10899DEN2014 A IN10899DEN2014 A IN 10899DEN2014A IN 2014DN10899 A IN2014DN10899 A IN 2014DN10899A
- Authority
- IN
- India
- Prior art keywords
- mir
- abundance
- inhibiting
- expression
- provides
- Prior art date
Links
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 4
- 108091034117 Oligonucleotide Proteins 0.000 abstract 3
- -1 miR-15a Proteins 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 108091057645 miR-15 stem-loop Proteins 0.000 abstract 2
- 108091031326 miR-15b stem-loop Proteins 0.000 abstract 2
- 108091027943 miR-16 stem-loop Proteins 0.000 abstract 2
- 108091030938 miR-424 stem-loop Proteins 0.000 abstract 2
- 108091063340 miR-497 stem-loop Proteins 0.000 abstract 2
- 108091070501 miRNA Proteins 0.000 abstract 2
- 239000002679 microRNA Substances 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261662772P | 2012-06-21 | 2012-06-21 | |
| US201361780352P | 2013-03-13 | 2013-03-13 | |
| PCT/US2013/046960 WO2013192486A1 (en) | 2012-06-21 | 2013-06-21 | Inhibitors of the mir-15 family of micro-rnas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN10899A true IN2014DN10899A (enExample) | 2015-09-11 |
Family
ID=49769409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN10899DEN2014 IN2014DN10899A (enExample) | 2012-06-21 | 2013-06-21 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9163235B2 (enExample) |
| EP (1) | EP2863956A4 (enExample) |
| JP (1) | JP2015525081A (enExample) |
| KR (1) | KR20150036140A (enExample) |
| CN (1) | CN104540527A (enExample) |
| AR (1) | AR091539A1 (enExample) |
| AU (1) | AU2013277033A1 (enExample) |
| BR (1) | BR112014032239A2 (enExample) |
| CA (1) | CA2876105A1 (enExample) |
| EA (1) | EA201590070A1 (enExample) |
| HK (1) | HK1209621A1 (enExample) |
| IN (1) | IN2014DN10899A (enExample) |
| MD (1) | MD20150006A2 (enExample) |
| MX (1) | MX2014015641A (enExample) |
| SG (1) | SG11201408460UA (enExample) |
| TW (1) | TW201406774A (enExample) |
| WO (1) | WO2013192486A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2864482A4 (en) | 2012-06-21 | 2016-02-10 | Miragen Therapeutics Inc | OLIGONUCLEOTIDE INHIBITORS COMPRISING A BLOCKED NUCLEIC ACID PATTERN |
| MX364814B (es) | 2013-03-15 | 2019-05-08 | Miragen Therapeutics Inc | Nucleosidos biciclicos unidos en puente. |
| US10443044B2 (en) | 2014-04-17 | 2019-10-15 | Ips Heart | Generating cardiac progenitor cells from pluripotent stem cells using isoxazole or isoxazole like compounds |
| WO2016022536A2 (en) | 2014-08-04 | 2016-02-11 | MiRagen Therapeutics, Inc. | Inhibitors of myh7b and uses thereof |
| MA40463A (fr) | 2014-08-07 | 2017-06-14 | Regulus Therapeutics Inc | Ciblage de micro-arn pour traiter des troubles métaboliques |
| HK1249108A1 (zh) | 2015-01-20 | 2018-10-26 | 米拉根医疗股份有限公司 | Mir-92抑制剂及其用途 |
| WO2017219170A1 (zh) * | 2016-06-19 | 2017-12-28 | 毛侃琅 | 特异抑制人 miRNA-29a 和 miR-424 表达的慢病毒载体的构建及其应用 |
| US20180193270A1 (en) | 2016-11-29 | 2018-07-12 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| CN106692175A (zh) * | 2016-12-26 | 2017-05-24 | 大连医科大学附属第二医院 | miR‑665‑3p抑制物在制备防治缺血再灌注损伤药物中的应用 |
| US10941403B2 (en) | 2018-04-02 | 2021-03-09 | Oregon Health & Science University | Microrna inhibitors as anti-cancer therapeutics |
| JP7692829B2 (ja) | 2019-07-30 | 2025-06-16 | 塩野義製薬株式会社 | Ｍｕｒｆ１を標的とする核酸医薬 |
| JP7825881B2 (ja) * | 2020-07-23 | 2026-03-09 | ヨハン ヴォルフガング ゲーテ－ウニヴェルズィテート フランクフルト | 心不全治療のためのｍｉＲＮＡのコンビナトリアル阻害 |
| CN113599540B (zh) * | 2021-05-27 | 2023-05-23 | 山西医科大学 | miRNA-195-5p在制备抑制或降低麦芽酚铝所致神经细胞损伤的试剂中的应用 |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2428570B1 (en) | 2001-09-28 | 2018-05-23 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Microrna molecules |
| CA2524569C (en) | 2002-05-03 | 2013-10-22 | Duke University | A method of regulating gene expression |
| US7892793B2 (en) | 2002-11-04 | 2011-02-22 | University Of Massachusetts | Allele-specific RNA interference |
| ATE546528T1 (de) | 2002-11-13 | 2012-03-15 | Univ Jefferson | Zusammensetzungen und verfahren zur diagnose und behandlung von krebs |
| EP2474630B1 (en) | 2002-12-20 | 2016-04-27 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
| KR20050115231A (ko) | 2003-02-10 | 2005-12-07 | 내셔날 인스티튜트 오브 어드밴스드 인더스트리얼 사이언스 앤드 테크놀로지 | 포유동물 세포의 조절 |
| US8145436B2 (en) | 2003-07-15 | 2012-03-27 | The Trustees Of The University Of Pennsylvania | Method and systems for identifying micro-RNA targets and synthesizing novel micro-RNAs and uses of the same |
| WO2005013901A2 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| US8106180B2 (en) | 2003-08-07 | 2012-01-31 | Whitehead Institute For Biomedical Research | Methods and products for expression of micro RNAs |
| WO2005017145A1 (ja) | 2003-08-13 | 2005-02-24 | Japan Biological Informatics Consortium | 機能性ｒｎａが制御する被制御遺伝子の同定・予測方法及びその利用方法 |
| EP1676914A4 (en) | 2003-09-22 | 2007-10-10 | Aichi Prefecture | TYPE OF PATHOLOGICAL LYMPHOMA AND DIAGNOSTIC EVALUATION METHOD |
| US20080045417A1 (en) | 2003-10-14 | 2008-02-21 | Jan Weiler | Oligonucleotide Microarray |
| US20050182011A1 (en) | 2003-11-13 | 2005-08-18 | Eric Olson | Inhibition of TRP channels as a treatment for cardiac hypertrophy and heart failure |
| JP4575923B2 (ja) | 2003-12-15 | 2010-11-04 | カレッジ オブ メディスン ポーチョン シーエイチエー ユニバーシティ インダストリー−アカデミック コーポレーション ファウンデーション | ヒトＥＳ細胞より分離された新規ｍｉＲＮＡ |
| EP1713938A2 (en) | 2004-02-09 | 2006-10-25 | Thomas Jefferson University | DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES |
| WO2005078096A2 (en) | 2004-02-09 | 2005-08-25 | University Of Massachusetts | Dual functional oligonucleotides for use in repressing mutant gene expression |
| CA2556435C (en) | 2004-02-13 | 2014-08-12 | The Rockefeller University | Anti-microrna oligonucleotide molecules |
| US8088902B2 (en) | 2004-04-05 | 2012-01-03 | The Rockefeller University | DNA virus microRNA and methods for inhibiting same |
| US20060134639A1 (en) | 2004-04-06 | 2006-06-22 | Huffel Christophe V | Method for the determination of cellular transcriptional regulation |
| US20050260648A1 (en) | 2004-04-06 | 2005-11-24 | Huffel Christophe V | Method for the determination of cellular transcriptional |
| DK1735459T3 (da) | 2004-04-07 | 2012-05-29 | Exiqon As | Fremgangsmåder til kvantificering af microRNA'er og små interfererende RNA'er |
| EP2471924A1 (en) | 2004-05-28 | 2012-07-04 | Asuragen, INC. | Methods and compositions involving microRNA |
| EP2990410A1 (en) | 2004-08-10 | 2016-03-02 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
| DK1797183T3 (da) | 2004-09-02 | 2012-10-01 | Univ Yale | Regulering af onkogener med mikrornas |
| FR2877350B1 (fr) | 2004-11-03 | 2010-08-27 | Centre Nat Rech Scient | IDENTIFICATION ET UTILISATION DE miRNAs IMPLIQUES DANS LA DIFFERENCIATION DE CELLULES ISSUES D'UNE LEUCEMIE MYELOIDE |
| ES2534300T3 (es) | 2004-11-12 | 2015-04-21 | Asuragen, Inc. | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN |
| US9550990B2 (en) | 2004-12-10 | 2017-01-24 | Ionis Pharmaceuticals, Inc. | Regulation of epigenetic control of gene expression |
| US20060185027A1 (en) | 2004-12-23 | 2006-08-17 | David Bartel | Systems and methods for identifying miRNA targets and for altering miRNA and target expression |
| WO2006071884A2 (en) | 2004-12-27 | 2006-07-06 | The Regents Of The University Of Michigan | Oligonucleotide based therapeutics |
| US20070099196A1 (en) | 2004-12-29 | 2007-05-03 | Sakari Kauppinen | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs |
| US8071306B2 (en) | 2005-01-25 | 2011-12-06 | Merck Sharp & Dohme Corp. | Methods for quantitating small RNA molecules |
| US20070065840A1 (en) | 2005-03-23 | 2007-03-22 | Irena Naguibneva | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS |
| JP2006292367A (ja) | 2005-04-05 | 2006-10-26 | Mitsubishi Rayon Co Ltd | ｍｉＲＮＡ検出用マイクロアレイ |
| WO2006108584A2 (en) | 2005-04-15 | 2006-10-19 | Cenix Bioscience Gmbh | Human marker genes and agents for cardiovascular disorders and artherosclerosis |
| EP1874936B1 (en) | 2005-04-19 | 2013-10-30 | BASF Plant Science GmbH | Improved methods controlling gene expression |
| DK2002003T3 (en) | 2005-05-27 | 2016-03-21 | Ospedale San Raffaele Srl | Gene vector comprising miRNA |
| US20070054287A1 (en) | 2005-05-31 | 2007-03-08 | Applera Corporation | Method for identifying medically important cell populations using micro rna as tissue specific biomarkers |
| WO2007053184A2 (en) | 2005-05-31 | 2007-05-10 | Cold Spring Harbor Laboratory | Methods for producing micrornas |
| US20090209621A1 (en) | 2005-06-03 | 2009-08-20 | The Johns Hopkins University | Compositions and methods for decreasing microrna expression for the treatment of neoplasia |
| US20070213292A1 (en) | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| AU2006279906B2 (en) | 2005-08-10 | 2012-05-10 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| CN101426912A (zh) | 2005-08-17 | 2009-05-06 | 瑟纳治疗公司 | 介导rna干扰的化学修饰短干扰核酸分子 |
| US8481505B2 (en) | 2005-09-12 | 2013-07-09 | The Ohio State University Research Foundation | Compositions and methods for the diagnosis and therapy of BCL2-associated cancers |
| US20070092882A1 (en) | 2005-10-21 | 2007-04-26 | Hui Wang | Analysis of microRNA |
| EP1951263A4 (en) | 2005-11-21 | 2009-11-18 | Johnson & Johnson Res Pty Ltd | MULTITARGETING DISTURBING RNAS WITH TWO ACTIVE STRANDS AND DESIGN AND APPLICATION METHODS |
| US20070259827A1 (en) | 2006-01-25 | 2007-11-08 | University Of Massachusetts | Compositions and methods for enhancing discriminatory RNA interference |
| AU2007212700A1 (en) | 2006-01-26 | 2007-08-16 | University Of Massachusetts | RNA interference agents for therapeutic use |
| WO2007092181A2 (en) | 2006-01-26 | 2007-08-16 | Unversity Of Massachusetts | Compositions and methods for modulating translational repression |
| EP2388328A1 (en) | 2006-01-27 | 2011-11-23 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of micrornas |
| EP1986697B1 (en) | 2006-02-17 | 2016-06-29 | GE Healthcare Dharmacon, Inc. | Compositions and methods for inhibiting gene silencing by rna interference |
| EP2522748A1 (en) | 2006-03-02 | 2012-11-14 | The Ohio State University | MicroRNA expression profile associated with pancreatic cancer |
| CA3042781C (en) | 2006-04-03 | 2021-10-19 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| US20080220423A1 (en) | 2006-05-19 | 2008-09-11 | Soren Moller | Oligonucleotide probes useful for detection and analysis of microRNA precursors |
| WO2007147067A2 (en) | 2006-06-14 | 2007-12-21 | Rosetta Inpharmatics Llc | Methods and compositions for regulating cell cycle progression |
| EP2035446A2 (en) | 2006-06-19 | 2009-03-18 | Københavns Universitet (University of Copenhagen) | Ribozyme mediated stabilization of polynucleotides |
| WO2008024499A2 (en) | 2006-08-25 | 2008-02-28 | Duke University | Methods for in vivo identification of endogenous mrna targets of micrornas |
| EP2145001A2 (en) | 2006-09-19 | 2010-01-20 | Asuragen, Inc. | Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention |
| US20090306181A1 (en) | 2006-09-29 | 2009-12-10 | Children's Medical Center Corporation | Compositions and methods for evaluating and treating heart failure |
| JP2010505427A (ja) | 2006-10-09 | 2010-02-25 | ジュリアス−マキシミリアンズ−ユニベルシタット ワーズブルグ | 心疾患の診断及び治療用マイクロＲＮＡ（ｍｉＲＮＡ） |
| WO2008147430A2 (en) | 2006-10-11 | 2008-12-04 | Nucleonics, Inc. | Microrna-formatted multitarget interfering rna vector constructs and methods of using the same |
| AU2007323469B2 (en) | 2006-11-23 | 2014-07-24 | Guangdong Maijinjia Biotechnology Co., Ltd | Oligonucleotides for modulating target RNA activity |
| EP2102341A2 (en) | 2006-12-08 | 2009-09-23 | Asuragen, INC. | Mirna regulated genes and pathways as targets for therapeutic intervention |
| WO2008073921A2 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Mir-126 regulated genes and pathways as targets for therapeutic intervention |
| EP2104737B1 (en) | 2006-12-08 | 2013-04-10 | Asuragen, INC. | Functions and targets of let-7 micro rnas |
| EP2104735A2 (en) | 2006-12-08 | 2009-09-30 | Asuragen, INC. | Mir-21 regulated genes and pathways as targets for therapeutic intervention |
| US20090137504A1 (en) | 2006-12-21 | 2009-05-28 | Soren Morgenthaler Echwald | Microrna target site blocking oligos and uses thereof |
| EP3536788A1 (en) | 2006-12-21 | 2019-09-11 | QIAGEN GmbH | Microrna target site blocking oligos and uses thereof |
| CA2671270A1 (en) | 2006-12-29 | 2008-07-17 | Asuragen, Inc. | Mir-16 regulated genes and pathways as targets for therapeutic intervention |
| WO2008109373A1 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting erbb gene expression and uses thereof |
| US9043994B2 (en) | 2007-03-13 | 2015-06-02 | Massachusetts Institute Of Technology | Cre-lox based gene knockdown constructs and methods of use thereof |
| WO2008116267A1 (en) | 2007-03-26 | 2008-10-02 | Crc For Asthma And Airways Ltd | Therapeutic targets and molecules |
| WO2008147839A1 (en) | 2007-05-23 | 2008-12-04 | Dharmacon, Inc. | Micro-rna scaffolds and non-naturally occurring micro-rnas |
| WO2009012263A2 (en) | 2007-07-18 | 2009-01-22 | The Trustees Of Columbia University In The City Of New York | Tissue-specific micrornas and compositions and uses thereof |
| BRPI0813527A2 (pt) | 2007-07-18 | 2014-12-30 | Univ Colorado | Expressão diferencial de micro-rnas em corações humanos que não falham versus que falham |
| US20090092980A1 (en) | 2007-07-20 | 2009-04-09 | Christoph Arenz | miRNA PROCESSING INHIBITOR EFFICACY ASSAYS AND SUBSTANCES |
| WO2009044895A1 (ja) | 2007-10-03 | 2009-04-09 | Kyowa Hakko Kirin Co., Ltd. | 標的遺伝子の発現を抑制する組成物 |
| DK2205737T3 (da) | 2007-10-04 | 2013-05-21 | Santaris Pharma As | Mikromirer |
| WO2009058818A2 (en) | 2007-10-29 | 2009-05-07 | The Board Of Regents Of The University Of Texas System | Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling |
| US8389485B2 (en) | 2007-10-29 | 2013-03-05 | University Of Massachusetts | Encapsulated nanoparticles for nucleic acid delivery |
| WO2009062169A2 (en) | 2007-11-09 | 2009-05-14 | The Board Of Regents Of The University Of Texas System | Micro-rnas of the mir-15 family modulate cardiomyocyte survival and cardiac repair |
| EP2520649A3 (en) * | 2007-11-23 | 2013-02-20 | Panagene, Inc. | MicroRNA antisense PNAs, compositions comprising the same, and methods for using and evaluating the same |
| EP2268811A1 (en) | 2008-03-07 | 2011-01-05 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
| EP2279267A4 (en) | 2008-03-27 | 2012-01-18 | Vascular Biosciences Inc | METHOD FOR IDENTIFYING NEW THERAPY CANDIDATES ON GENE EXPRESSION ANALYSIS IN DISEASES RELATED TO VACCINES |
| EP2105145A1 (en) | 2008-03-27 | 2009-09-30 | ETH Zürich | Method for muscle-specific delivery lipid-conjugated oligonucleotides |
| US20090326049A1 (en) | 2008-04-04 | 2009-12-31 | Alexander Aristarkhov | Blocking oligos for inhibition of microrna and sirna activity and uses thereof |
| US20100113284A1 (en) | 2008-04-04 | 2010-05-06 | Alexander Aristarkhov | Small interfering rna (sirna) target site blocking oligos and uses thereof |
| US8258111B2 (en) | 2008-05-08 | 2012-09-04 | The Johns Hopkins University | Compositions and methods related to miRNA modulation of neovascularization or angiogenesis |
| CA2726052A1 (en) | 2008-06-04 | 2009-12-10 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression through endogenous small rna targeting of gene promoters |
| WO2010036939A2 (en) | 2008-09-26 | 2010-04-01 | University Of Southern California | A system for synergistic expression of multiple small functional rna elements |
| EP2447274B1 (en) | 2008-10-24 | 2017-10-04 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
| WO2010126355A1 (en) | 2009-04-29 | 2010-11-04 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Means and methods for counteracting, preventing and/or determining heart failure, or a risk of heart failure |
| MA33488B1 (fr) | 2009-06-08 | 2012-08-01 | Miragen Therapeutics | Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn |
-
2013
- 2013-06-19 US US13/921,537 patent/US9163235B2/en not_active Expired - Fee Related
- 2013-06-21 KR KR1020157001535A patent/KR20150036140A/ko not_active Withdrawn
- 2013-06-21 AU AU2013277033A patent/AU2013277033A1/en not_active Abandoned
- 2013-06-21 CA CA2876105A patent/CA2876105A1/en not_active Abandoned
- 2013-06-21 MX MX2014015641A patent/MX2014015641A/es unknown
- 2013-06-21 MD MDA20150006A patent/MD20150006A2/ro not_active Application Discontinuation
- 2013-06-21 HK HK15110356.0A patent/HK1209621A1/xx unknown
- 2013-06-21 JP JP2015518597A patent/JP2015525081A/ja active Pending
- 2013-06-21 WO PCT/US2013/046960 patent/WO2013192486A1/en not_active Ceased
- 2013-06-21 EA EA201590070A patent/EA201590070A1/ru unknown
- 2013-06-21 BR BR112014032239A patent/BR112014032239A2/pt not_active IP Right Cessation
- 2013-06-21 CN CN201380039961.7A patent/CN104540527A/zh active Pending
- 2013-06-21 TW TW102122289A patent/TW201406774A/zh unknown
- 2013-06-21 IN IN10899DEN2014 patent/IN2014DN10899A/en unknown
- 2013-06-21 SG SG11201408460UA patent/SG11201408460UA/en unknown
- 2013-06-21 EP EP13806131.2A patent/EP2863956A4/en not_active Withdrawn
- 2013-06-24 AR ARP130102219 patent/AR091539A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201590070A1 (ru) | 2015-04-30 |
| CA2876105A1 (en) | 2013-12-27 |
| US9163235B2 (en) | 2015-10-20 |
| HK1209621A1 (en) | 2016-04-08 |
| SG11201408460UA (en) | 2015-01-29 |
| AR091539A1 (es) | 2015-02-11 |
| EP2863956A4 (en) | 2016-01-20 |
| WO2013192486A1 (en) | 2013-12-27 |
| MX2014015641A (es) | 2015-07-14 |
| KR20150036140A (ko) | 2015-04-07 |
| CN104540527A (zh) | 2015-04-22 |
| US20130345288A1 (en) | 2013-12-26 |
| MD20150006A2 (ro) | 2015-06-30 |
| TW201406774A (zh) | 2014-02-16 |
| BR112014032239A2 (pt) | 2017-08-01 |
| EP2863956A1 (en) | 2015-04-29 |
| JP2015525081A (ja) | 2015-09-03 |
| AU2013277033A1 (en) | 2015-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD20150006A2 (ro) | Inhibitori de micro-ARN din familia miR-15 | |
| MX2013005875A (es) | Inhibidores de microarn que comprenden nucleotidos bloqueados. | |
| ZA202002019B (en) | Serpinc1 irna compositions and methods of use thereof | |
| UA117098C2 (uk) | Сполука, що містить модифікований олігонуклеотид | |
| BR112014025020A2 (pt) | composições e métodos para inibição da expressão do gene alas1 | |
| MX2018013216A (es) | Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6). | |
| MX390699B (es) | Composiciones y metodos para inhibicion de genes para apolipoproteina c-iii (apoc3). | |
| MX359548B (es) | Agentes de iarn modificados. | |
| MX355408B (es) | Inhibidores a base de oligonucleotidos que comprenden un motivo de acido nucleico bloqueado. | |
| UA115652C2 (uk) | Сполука, що містить модифікований олігонуклеотид, комплементарна mir-21 | |
| WO2012142313A8 (en) | Micro-rna inhibitors and their uses in disease | |
| WO2012024396A3 (en) | Compositions and methods for delivering nucleic acid molecules and treating cancer | |
| PH12016500574A1 (en) | Compositions and methods for inhibiting expression of the alas1 gene | |
| GB201118656D0 (en) | New compounds | |
| AR083445A1 (es) | siARN CONTRA LA FIBROSIS | |
| MX2018006445A (es) | Oligonucleotidos antisentido de interleucina-34 (il-34) y metodos de uso de los mismos. | |
| MX368084B (es) | siRNA Y SU USO EN LA PREPARACIÓN DE UN MEDICAMENTO PARA USARSE EN UN MÉTODO PARA EL TRATAMIENTO DE UN TRANSTORNO OCULAR. | |
| PL398796A1 (pl) | Zastosowanie czasteczek miRNA oraz antagomiru dla miRNA w diagnostyce, zapobieganiu i leczeniu stwardnienia rozsianego | |
| NZ776080A (en) | Modified rnai agents | |
| NZ728207A (en) | Oligonucleotide-based inhibitors comprising locked nucleic acid motif |